Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025
AMPKα2 attenuates doxorubicin induced ferroptosis by promoting NCOA4 degradation in triple negative breast cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Xinjun, Si Zizhen, Li Linbo, Zhou Miao, Lee Ki-Young, Wang Xidi
Аннотация
AIMS: Triple negative breast cancer (TNBC) is an aggressive type of breast cancer with limited therapeutic options and frequent chemoresistance. AMPK catalytic α-subunit 2 (AMPKα2) is implicated in development of chemoresistance in various cancers. However, the role of AMPKα2 in doxorubicin (DOX)-resistance in TNBC remains to be investigated.
METHODS: The levels of AMPKα2 in DOX-resistant TNBC was examined by Western blotting. AMPKα2 functions on DOX induced ferroptosis were assessed by lipid peroxidation, intracellular iron, MDA, and GSH detection assays. Western blotting, qRT-PCR, co-IP, immunofluorescence staining and KFERQ-mCherry reporter assay were performed to demonstrate the role of AMPKα2 and its association with NCOA4 degradation.
RESULTS: AMPKα2, rather than AMPKα1, was upregulated in DOX-resistant TNBC cells. AMPKα2 inhibited DOX-induced ferroptosis by suppressing NCOA4. AMPKα2 phosphorylated NCOA4 at S151, which enhanced the recognition of NCOA4 by HSC70, and the formation of NCOA4/HSC70/LAMP-2A complex to initiate CMA pathway mediated NCOA4 degradation. S151A mutation or AMPKα inhibitor abolished these biological effects and increased the vulnerability to DOX-induced ferroptosis.
CONCLUSIONS: AMPKα2 suppressed DOX-induced ferroptosis through phosphorylating NCOA4 at S151 to induce its CMA pathway dependent degradation. Targeting AMPKα2 could be a potential strategy to overcome DOX resistance in TNBC patients.
METHODS: The levels of AMPKα2 in DOX-resistant TNBC was examined by Western blotting. AMPKα2 functions on DOX induced ferroptosis were assessed by lipid peroxidation, intracellular iron, MDA, and GSH detection assays. Western blotting, qRT-PCR, co-IP, immunofluorescence staining and KFERQ-mCherry reporter assay were performed to demonstrate the role of AMPKα2 and its association with NCOA4 degradation.
RESULTS: AMPKα2, rather than AMPKα1, was upregulated in DOX-resistant TNBC cells. AMPKα2 inhibited DOX-induced ferroptosis by suppressing NCOA4. AMPKα2 phosphorylated NCOA4 at S151, which enhanced the recognition of NCOA4 by HSC70, and the formation of NCOA4/HSC70/LAMP-2A complex to initiate CMA pathway mediated NCOA4 degradation. S151A mutation or AMPKα inhibitor abolished these biological effects and increased the vulnerability to DOX-induced ferroptosis.
CONCLUSIONS: AMPKα2 suppressed DOX-induced ferroptosis through phosphorylating NCOA4 at S151 to induce its CMA pathway dependent degradation. Targeting AMPKα2 could be a potential strategy to overcome DOX resistance in TNBC patients.